57. 特発性拡張型心筋症 [臨床試験数:12,薬物数:23(DrugBank:11),標的遺伝子数:9,標的パスウェイ数:31]
Searched query = "Idiopathic dilated cardiomyopathy"
The queries were searched in Public_title, Scientific_title, and Condition of the data. Export date: 11/20/2019, 11/21/2019. Trials are sorted by Date_enrolment from most recent to oldest in the table.
No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | NCT02987322 | November 2015 | 9 January 2017 | Honey in Idiopathic Dilated Cardiomyopathy | Honey Supplementation in Children With Idiopathic Dilated Cardiomyopathy: A Randomized Controlled Study | Idiopathic Dilated Cardiomyopathy | Dietary Supplement: honey | mamdouh abdulmaksoud abdulrhman | Not recruiting | 2 Years | 12 Years | Both | 50 | Phase 2/Phase 3 | ||
2 | NCT02078141 | June 2014 | 11 June 2018 | 18F-deoxyglucose (FDG) PET-CMD | Monocentric, Prospective, Uncontrolled Pilot Study of Extra Cardiomyocytary Fixation Profile in 18F-fluorodeoxyglucose (FDG) Positron Emission Tomography in Patients With Dilated Cardiomyopathy. | Patients With Idiopathic Dilated Cardiomyopathy | Drug: 18F-deoxyglucose (FDG) | Nantes University Hospital | Not recruiting | 18 Years | N/A | All | 30 | N/A | France | |
3 | NCT02033278 | January 6, 2014 | 11 June 2018 | Infusion Intracoronary of Mononuclear Autologous Adult no Expanded Stem Cells of Bone Marrow on Functional Recovery in Patients With Idiopathic Dilated Cardiomyopathy and Heart Failure. | Multicenter Phase IIb Clinical Trial, Double-blind, Randomized, Controlled Placebo for to Assess the Efficacy of Intracoronary Infusion of Autologous Adult Stem Cells Mononuclear Marrow Unexpanded on Functional Recovery in Patients With Idiopathic Dilated Cardiomyopathy and Heart Failure. | Idiopathic Dilated Cardiomyopathy | Drug: Infusion of autologous mononuclear bone marrow cells;Drug: Placebo infusion | Andalusian Initiative for Advanced Therapies - Fundación Pública Andaluza Progreso y Salud | Iniciativa Andaluza en Terapias Avanzadas | Recruiting | 18 Years | 70 Years | All | 51 | Phase 2 | Spain |
4 | NCT02256501 | June 2013 | 16 December 2017 | Intracoronary Transplantation of Bone Marrow Derived Mononuclear Cells in Pediatric Cardiomyopathy | Intracoronary Transplantation of Autologous Bone Marrow Derived Mononuclear Cells (MNC) in Idiopathic Dilated Cardiomyopathy in Pediatric Patients: Clinical Trial Phase I/II | Cardiomyopathy | Biological: Mono Nuclear Cell (MNC) transplantation | Nasser Aghdami MD., PhD | Not recruiting | 1 Year | 16 Years | All | 30 | Phase 1/Phase 2 | Iran, Islamic Republic of | |
5 | NCT02292043 | May 2013 | 19 February 2015 | Effects of HTEA ON Heart Failure Secondary to Idiopathic Dilated Cardiomyopathy or Post-myocardial Infarction | Effects of HTEA ON Heart Failure Secondary to Idiopathic Dilated Cardiomyopathy or Post-myocardial Infarction | Congestive Heart Failure | Drug: HTEA | Harbin Medical University | Recruiting | 20 Years | 80 Years | Both | 60 | N/A | China | |
No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
6 | NCT01219452 | October 2010 | 19 February 2015 | Intramuscular Injection of Mesenchymal Stem Cell for Treatment of Children With Idiopathic Dilated Cardiomyopathy | Effects of Intramuscular Injection of Umbilical Cord Mesenchymal Stem Cell on the Ventricular Function of Children With Idiopathic Dilated Cardiomyopathy | Dilated Cardiomyopathy | Biological: umbilical cord mesenchymal stem cells | Qingdao University | Not recruiting | 1 Year | 14 Years | Both | 30 | Phase 1/Phase 2 | China | |
7 | EUCTR2009-013112-12-GB | 22/04/2010 | 4 August 2015 | Randomised Controlled Trial To Compare The effects of G-CSF(Granocyte™) And Autologous Bone Marrow Progenitor Cells On Quality Of Life And Left Ventricular Function In Patients with Idiopathic Dilated Cardiomyopathy - REGENERATE-DCM | Randomised Controlled Trial To Compare The effects of G-CSF(Granocyte™) And Autologous Bone Marrow Progenitor Cells On Quality Of Life And Left Ventricular Function In Patients with Idiopathic Dilated Cardiomyopathy - REGENERATE-DCM | Idiopathic Dilated Cardiomyopathy Level: LLT Classification code 10056419 Term: Dilated Cardiomyopathy | Trade Name: Granocyte Lenograstim Product Name: GRANOCYTE - 34 million IU (Lenograstim rHuG-CSF) Product Code: PL 12185/0002 & PL 12185/0005(WATER FOR INJECTION) Pharmaceutical Form: Powder and solvent for solution for injection | Barts & the London NHS Trust | Not Recruiting | Female: yes Male: yes | United Kingdom | |||||
8 | EUCTR2007-003088-36-ES | 15/02/2008 | 19 March 2012 | Efecto de la Infusión Intracoronaria de Células Progenitoras de Médula Ósea sobre la Regeneración Miocárdica en Pacientes con Miocardiopatía Dilatada. Estudio Cínico-Biológico. Effects of intracoronary infusion of bone marrow-derived progenitor cells on myocardial regeneration in patients with non-ischemic dilated cardiomyophathy. A clinico-biological study | Efecto de la Infusión Intracoronaria de Células Progenitoras de Médula Ósea sobre la Regeneración Miocárdica en Pacientes con Miocardiopatía Dilatada. Estudio Cínico-Biológico. Effects of intracoronary infusion of bone marrow-derived progenitor cells on myocardial regeneration in patients with non-ischemic dilated cardiomyophathy. A clinico-biological study | Miocardiopatía dilatada de origen idiopático Idiopathic Dilated Cardiomyopathy MedDRA version: 9.1 Level: LLT Classification code 10059868 Term: Non-ischemic dilated cardiomyopathy | Product Name: Bone marrow mononuclear cells Product Code: BMMNC Pharmaceutical Form: Injection* | AININCAR | Authorised | Female: yes Male: yes | Spain | |||||
9 | NCT02115581 | September 2006 | 19 October 2017 | Coenzyme Q10 Supplementation in Children With Idiopathic Dilated Cardiomyopathy | Effect of Coenzyme Q10 (Ubiquinone) Supplementation on Ventricular Function of Children With Idiopathic Dilated Cardiomyopathy.A Randomised Clinical Trial | Dilated Cardiomyopathy | Drug: Coenzyme Q10;Drug: Placebo | University of Tehran | Not recruiting | 6 Months | 18 Years | All | 38 | Phase 4 | Iran, Islamic Republic of | |
10 | NCT01917149 | March 2005 | 19 February 2015 | Supramaximal Titrated Inhibition of RAAS in Dilated Cardiomyopathy | Efficacy and Safety Study of Supramaximal Titrated Inhibition of RAAS in Idiopathic Dilated Cardiomyopathy | Dilated Cardiomyopathy | Drug: Benazepril;Drug: Valsartan;Drug: Metoprolol | Xijing Hospital | Not recruiting | 18 Years | 70 Years | Both | 480 | Phase 4 | China | |
No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
11 | NCT00281255 | June 2003 | 19 February 2015 | Intravenous Allopurinol to Improve Heart Function in Individuals With Dilated Cardiomyopathy | Allopurinol and Cardiac Function Pilot Study in Idiopathic Dilated Cardiomyopathy | Cardiovascular Diseases;Cardiomyopathy, Dilated;Heart Diseases;Heart Failure, Congestive | Drug: Allopurinol;Drug: Dobutamine | University of Pennsylvania | National Heart, Lung, and Blood Institute (NHLBI) | Not recruiting | 18 Years | N/A | Both | 0 | Phase 1/Phase 2 | United States |
12 | NCT01798992 | September 2000 | 20 August 2018 | Effect of Beta-blockers on Structural Remodeling and Gene Expression in the Failing Human Heart | Beta-blocker Effect on Structural Remodeling and Gene Expression in the Failing Human Heart | Idiopathic Dilated Cardiomyopathy | Drug: Carvedilol;Drug: Metoprolol succinate;Drug: Metoprolol succinate + doxazosin | University of Colorado, Denver | National Heart, Lung, and Blood Institute (NHLBI);GlaxoSmithKline;AstraZeneca | Not recruiting | 18 Years | N/A | All | 56 | Phase 4 | United States |